Article Text

PDF
Cutaneous angiosarcoma: a current update
  1. Elina Shustef1,
  2. Viktoryia Kazlouskaya2,
  3. Victor G Prieto1,
  4. Doina Ivan1,
  5. Phyu P Aung1
  1. 1Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  2. 2Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, New York, USA
  1. Correspondence to Dr Phyu P Aung, Department of Pathology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; aungpatho{at}gmail.com

Abstract

Cutaneous angiosarcoma (cAS) is a rare malignant neoplasm with variable clinical presentation. Although a distinct vascular tumour, cAS shares many overlapping histopathological features with other vasoformative and epithelioid tumours or ‘mimickers’. cAS shows aggressive behaviour and carries a grave prognosis, thus early diagnosis is of paramount importance to achieve the best possible outcomes. Recently, several genetic studies were conducted leading to the identification of novel molecular targets in the treatment of cAS. Herein, we present a comprehensive review of cAS with discussion of its clinical, histopathological and molecular aspects, the differential diagnosis, as well as current therapies including ongoing clinical trials.

  • cutaneous vascular lesions
  • angiosarcoma
  • histologic mimickers
  • histopathology
  • immunohistochemistry
  • molecular and therapy

Statistics from Altmetric.com

Footnotes

  • Handling editor Runjan Chetty

  • Contributors ES and VK wrote the draft and reviewed by DI, VGP and PPA. PPA also generated the idea of the study.

  • Competing interests None declared.

  • Provenance and peer review Not commssioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.